the World health organization (WHO) recommends the widespread use of a malaria vaccine in children in Africa and other areas with a high prevalence of Malaria. This is a great achievement in the long battle against the deadly Illness.
Malaria is a parasite disease that has existed for millennia and is mainly transmitted through mosquito bites. More than 400,000 people die worldwide each year, mostly in Sub-Saharan Africa Africa. More than 260,000 children under the age of 5 die each year Malaria.
The road to an effective malaria vaccine is long Vaccinations previously used and showing modest effectiveness, Live Science reported earlier.
The WHO-approved vaccine – called RTS, S or Mosquirix – has been in development for more than 30 years and strengthens the immune system against Plasmodium falciparum, the deadliest malaria parasite and the most common in Africa.
It is the first vaccine to conduct large-scale clinical trials and has been shown to be the Malaria, also life-threatening Malaria, in young children in Africa, said the WHO.
It is also the first vaccine developed against a parasite-caused disease, according to the New York Times.
“This is a historic moment. The long-awaited childhood malaria vaccine is a breakthrough in science, child health and malaria control. ” Dr. Tedros Adhanom Gebreesus, WHO director general, said in a statement on Wednesday (October 6).
“Using this vaccine in addition to existing malaria prevention products can save tens of thousands of young lives each year.”
In large-scale clinical trials, the Vaccination, Developed by the UK health care company GlaxoSmithKline, prevented about 4 out of 10 cases of malaria – an effectiveness of 39 percent – in children who received the four doses over a period of four years, the WHO said. The vaccine prevents 3 out of 10 cases – 29% effectiveness – of severe Malaria.
Based on the results of clinical studies, the WHO has recommended testing the vaccine in selected areas in Ghana, Kenya and Malawi.
As of 2019, more than 800,000 children in these countries have been vaccinated through these programs, according to the WHO.
the Vaccination, given in four doses to children as young as five months old has been shown to be safe and results in a 30% reduction in the number of fatalities of Malaria, even if they are distributed in areas where insecticide treated nets are widespread and where there are good treatment options.
At present, malaria in high prevalence areas is mainly combated by spraying insecticides once or twice a year or sleeping under mosquito nets treated with insecticides.
Other to learn, published in September in the New England Journal of Medicine, found that when children are given an anti-malarial drug with the Vaccination, the combination reduced hospital stays for severe malaria by 70.5% and deaths by 72.9% compared to anti-malarial drugs.
A model to learn published November 2020 in the journal PLOS Medicine that the vaccine could prevent 5.3 million cases and 24,000 deaths each year in children aged 5 years and younger.
If the global vaccine union Gavi determines that the malaria vaccine is indeed a good investment, the organization will buy the vaccine Vaccinations for countries that want it, according to the Times.
Other candidates for the malaria vaccine are currently being tested. One of these VaccinationsDeveloped by Oxford University researchers, showed 77% efficacy in early clinical trials – the only malaria vaccine to surpass WHO’s target of 75% or more efficacy by 2030, reports Live Science. According to The Guardian, large-scale processes are now beginning Vaccination.
A second malaria vaccine would be “very useful” in the fight Malaria, especially by supporting the expected high demandsaid the WHO.
/ OFF messages